GlaxoSmithKline PLC Directorate Change (7553L)

TIDMGSK

RNS Number : 7553L

GlaxoSmithKline PLC

21 July 2017

GlaxoSmithKline plc (the "Company")

Board and Committee changes

GSK today announces that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert. Dr Glimcher will join the Board on 1 September 2017.

Philip Hampton, Chairman of GlaxoSmithKline plc, said: "I am delighted Laurie is joining the Board. Laurie brings a wealth of expertise in scientific and medical innovation and public health which will be invaluable to GSK. "

Dr Glimcher is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana-Farber Cancer Institute.

In addition to a number of senior leadership positions held at both Harvard Medical School and Harvard School of Public Health, Dr Glimcher has also served as Stephen and Suzanne Weiss Dean and Professor of Medicine at Weill Cornell Medical College and as an Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center.

Dr Glimcher is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation. She is a Non-Executive Director of the Parker Institute for Cancer Immunotherapy and of the Waters Corporation, where she also serves on their Corporate Governance Committee. Dr Glimcher recently decided to step down from the Board of Bristol-Myers Squibb Co (BMS) after serving for 20 years on its Board.

Dr Glimcher has recently been awarded the Kober Medal from the American Association of Physicians for a lifetime of achievements in the field of internal medicine. She has also received the L'Oreal Laureate Award for her discoveries in immunology, and the Marion Fay Spencer award for her scholarship and commitment to the application of sciences to healthcare. She is also a member of the Lasker Award Jury, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine, a Member of the National Academy of Sciences and a Fellow of the Royal Society of Biology.

On joining the Board Dr Glimcher will become a member of the Board's Science and Audit & Risk Committees.

V A Whyte

Company Secretary

21 July 2017

Notes

1. As Non-Executive Director of GSK, Dr Glimcher will receive standard annual fees of GBP85,000 per annum. She will also receive a further GBP30,000 in respect of her additional duties as a Board Scientific and Medical Expert. To enhance the link between Non-Executive Directors and shareholders, at least 25% of her fees will be paid in the form of Ordinary Shares and allocated to a share account, and she will be able to invest part or all of the balance of her fees into the same share account.

2. The Board has determined that Dr Glimcher will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Dr Glimcher's appointment in accordance with Listing Rule 9.6.13R.

3. "Scientific and Medical Expert" - The Board designates Non Executive Directors whose expertise or backgrounds as renowned medical scientists, researchers, or physicians mean that they are able to bring scientific or industry expertise to the Board's deliberations.

   4.   With effect from 1 September 2017, the composition of the Board of GSK will be as follows: 
 
Sir Philip Hampton          Non-Executive Chairman 
Ms Emma Walmsley            Chief Executive Officer 
Mr Simon Dingemans          Chief Financial Officer 
Dr Patrick Vallance         President, R&D 
Professor Sir Roy Anderson  Independent Non-Executive Director 
Mr Vindi Banga              Senior Independent Non-Executive Director 
Dr Vivienne Cox             Independent Non-Executive Director 
Ms Lynn Elsenhans           Independent Non-Executive Director 
Dr Jesse Goodman            Independent Non-Executive Director 
Dr Laurie Glimcher          Independent Non-Executive Director 
Ms Judy Lewent              Independent Non-Executive Director 
Mr Urs Rohner               Independent Non-Executive Director 
 

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 
GSK enquiries: 
                             Simon Steel       [phone]   (London) 
                                                5502 
                             Eleanor Bunch     [phone]   (London) 
                                                5502 
 
US Media enquiries:          Sarah Alspach     [phone]   (Washington, 
                                                                  DC) 
                             Sarah Spencer     [phone]   (Philadelphia) 
 
Analyst/Investor enquiries:  Sarah Elton-Farr  [phone]   (London) 
                                                5194 
                             Tom Curry         + 1 215 751 5419  (Philadelphia) 
                             Gary Davies       [phone]   (London) 
                                                5503 
                             James Dodwell     [phone]   (London) 
                                                2406 
                             Jeff McLaughlin   [phone]   (Philadelphia) 
 
 
Cautionary statement regarding forward-looking statements 
 GSK cautions investors that any forward-looking statements or projections made by GSK, including 
 those made in this announcement, are subject to risks and uncertainties that may cause actual 
 results to differ materially from those projected. Such factors include, but are not limited 
 to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F 
 for 2016. 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAFMGZNLMRGNZG

(END) Dow Jones Newswires

July 21, 2017 06:00 ET (10:00 GMT)